PharmEng International Inc. (the “Company”) is publicly listed trading on the TSX Venture Exchange (the “TSXV”), with a ticker symbol “PII”.
Headquartered in Toronto, Canada, the Company wholly-owns PharmEng USA, Inc. (“PUSA”), PharmEng China Inc., PharmEng Taiwan Inc., and PharmEng Technology Inc. (“PTI”) which wholly owns Keata Pharma Inc. (“Keata”).
PharmEng is engaged in two rapidly growing businesses:
(i) a broad-based pharmaceutical consulting business (PTI) that serves the pharmaceutical, biotechnology and medical device industries in North America and internationally, and,
(ii) a contract pharmaceutical manufacturing business (Keata) serving North American pharmaceutical customers.....more
